Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects
Journal of Cell Communication and Signaling · 2026-03 · 20 (1)
DOI: 10.1002/ccs3.70066 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cell Communication and Signaling, online erschienen am 02.03.2026. Verfasst von Xintao Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Discovery Biology Shouyao Holdings (Beijing) Co. Ltd Beijing China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
MALT1, a multifunctional protease molecule, plays a pivotal role in the adaptive immunity by regulating immune cell survival, proliferation and activation through the nuclear transcription factor‐κB (NF‐κB) signaling pathway by scaffold and protease activities. Aberrant activation of MALT1 is implicated in the pathogenesis of hematologic malignancies, particularly diffuse large B‐cell lymphoma, and select solid tumors. Emerging research studies highlight MALT1 inhibitors as promising therapeutic agents for B‐cell malignancies, with several candidates demonstrating preclinical and clinical efficacy. Notably, agents such as safimaltib (JNJ‐67856633) have shown manageable safety profiles and preliminary antitumor activity in early‐phase trials for relapsed/refractory B‐cell malignancies. However, MALT1‐targeted therapy poses a dual challenge: although inhibiting oncogenic signaling and tumor cell proliferation, it also disrupts immunosuppressive Treg function, risking autoimmune toxicity by compromising the tumor microenvironment. This review systematically analyzes MALT1's oncogenic roles across cancers, clarifies inhibitor mechanisms, and evaluates translational challenges and strategic opportunities for precision oncology and combination immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Discovery Biology Shouyao Holdings (Beijing) Co. Ltd Beijing China.
- National Anti- Drug Laboratory Beijing Regional Center Beijing China.
- College of Basic Medical Qingdao Binhai University Qingdao China.
ORCID-Profile: Dejiu Zhang
Zitieren
APA
Cao, X., Wang, P., Ji, Y., Sun, Y., & Zhang, D. (2026). Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects. Journal of Cell Communication and Signaling, 20(1). https://doi.org/10.1002/ccs3.70066
Vancouver
Cao X, Wang P, Ji Y, Sun Y, Zhang D. Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects. Journal of Cell Communication and Signaling. 2026;20(1). doi:10.1002/ccs3.70066
BibTeX
@article{Cao2026,
author = {Cao, Xintao and Wang, Peixia and Ji, Yuan and Sun, Yongliang and Zhang, Dejiu},
title = {Therapeutic targeting of MALT1 in oncology: Mechanism, inhibitor development, and clinical prospects},
journal = {Journal of Cell Communication and Signaling},
year = {2026},
volume = {20},
number = {1},
doi = {10.1002/ccs3.70066}
}
EUVIMED